SWEET e.V. is a unique consortium, including not only SWEET Centres of Reference, but also several diabetes-related non-profit organisations and leading pharmaceutical and medical technology companies.

The following non-profit organisations were involved in the initial SWEET project (2008 till 2011) and some are still official members of SWEET e.V.:


ISPAD is a professional organisation whose aims are to promote clinical and basic science, education and advocacy in childhood and adolescent diabetes. The strength of ISPAD lies in the scientific and clinical expertise in childhood and adolescent diabetes of its members. ISPAD is the only international society focusing specifically on all types of childhood diabetes.
ISPAD as a registered charity has given the formal accreditation as scientific society with worldwide recognition for SWEET e.V.
Associated person: R. Hanås, President of ISPAD


FEND has established a unique voice for nurses working in the field of diabetes care, research and education. FEND’s mission is to promote the delivery of evidence based care for people with diabetes throughout Europe by promoting acceptable standards and equity of care for people with diabetes and by influencing European health care policy.
Associated person: Anne Felton


IDF European Region as the only European advocate for people with diabetes and their healthcare providers, works together with its member associations and other diabetes stakeholders to enhance the lifes of people with diabetes. IDF Europe has more than 62 diabetes associations in some 43 countries in its membership. Many of these associations are made up of both people with diabetes and health care professionals. The mission of the IDF is to promote diabetes care, prevention and cure worldwide.
Associated person: Laszlo Madacsy



PCDE provides a focal point for primary care clinicians and their patients and its purpose is to promote high standards of care throughout Europe. The mission of PCDE is the implementation of evidence based medicine into daily practice as well as the promotion of diabetes education and research in primary care. Therefore the around 4000 members will create an information system for members and a network for active contacts with other groups working in the field of primary care and diabetes.
Associated person: Imre Rurik


The Foundation Hannoversche Kinderheilanstalt was built in 1863.
It was the first institution of medical care for children in Hannover.
The Foundation enables today:

  • the medical care of annual 30.000  sick children and adolescents
  • social pediatric care of underprivileged and handicapped children
  • rehabilitation of deaf born or suffered late - onset deafness
  • pedagogic -therapeutic care of children
  • advancement of professional education as well as advanced training of physicians, health are professionals and other qualified personnel

 Diabetes Foundation UK  

The Diabetes Foundation UK has the objectives:

  • to support and advance research in the field of diabetes, particularly juvenile diabetes in the United Kingdom and throughout the world
  • to provide material of an educational  and informational nature to persons who are interested in or affected by diabetes


Medtronic Foundation focus the grantmaking

  • on health, education and community, and works closely with the nonprofit partners to increase their impact in communities around the world
  • in areas where they can make unique and positive contributions, while helping their nonprofit partners increase the impact of their good work.
  • nationally and across the globe to improve the health and vitality of people and communities worldwide




SWEET e.V. acknowledges with gratitude the support from the following SWEET e.V. corporate members – in alphabetical order: Bayer Health Care – Diabetes Care, Boehringer Ingelheim Phama, DexCom Inc., Johnson & Johnson Diabetes Institute, Lilly Diabetes Excellence Centre, Medtronic Europe, NovoNordisk A/S, Roche, Sanofi.

 Bayer   Bayer HealthCare Diabetes Care supports customers in 100 countries. Since the introduction of Clinitest® reagent tablets in 1941, Bayer has led the way in diabetes care product innovation. The company changed the face of diabetes care in 1969 when it introduced the first portable blood glucose meter and test strips. Bayer HealthCare further innovated diabetes management by being the first company to introduce a suite of blood glucose monitors with No Coding™ technology. The BREEZE2® and CONTOUR® blood glucose monitoring systems offer people with diabetes an unparalleled choice in diabetes management systems.


DexCom, Inc., headquartered in California, is focused on pioneering innovative continuous glucose monitoring technologies to help people with diabetes and in the Intensive Care Unit of hospitals. The DexCom Seven System is approved for up to 7 days of continuous use, providing a current glucose value, 1-hr, 3-hr and 9-hr trending screens and customizable alerts to allow patients to take corrective actions regarding their glucose levels.

 johnson   Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturer founded in 1886.


Lilly ( is an innovation-driven pharmaceutical company with a long tradition in diabetes. We are developing a growing portfolio of innovative pharmaceutical products by applying research from our own worldwide laboratories, by collaborating with eminent scientific organizations, by making use of up-to-date technological tools, and by providing excellent service to our customers. Lilly Diabetes is committed to the success in the fight against diabetes by complementing therapeutic portfolio with non-pharmaceutical approaches. This commitment is exemplified by numerous programs focused on advancing the scientific and clinical understanding of diabetes and improving diabetes education and care. As a sign of Lilly´s commitment to diabetes, Diabetes Excellence Center (DEC) was established in Germany in 2007 to enhance diabetes prevention, awareness, education, research and patient care in Europe. DEC is also partnering with organizations such as SWEET to improve diabetes care in Europe.    


Medtronic, Inc., headquartered in Minneapolis, is the global leader in medical technology, alleviating pain, restoring health and extending life for millions of people around the world. Medtronic provides physicians and hospitals with products and therapies which each year contribute improve the life of more than 5 million patients. Medtronic’s European headquarter is in Tolochenaz (VD), Switzerland. The Diabetes division at Medtronic ( is the world leader in advanced diabetes management solutions, including integrated diabetes management systems, insulin pump therapy, continuous glucose monitoring systems and therapy management software. For more information please visit and


Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,550 employees in 80 countries, and markets its products in 179 countries. For more information please visit


Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 30 years, the Accu-Chek brand has been committed to enable people with diabetes to live life as normal and active as possible as well as to help healthcare professionals manage their patient’s condition in an optimal way. Today, the Accu-Chek portfolio offers people with diabetes and healthcare professionals innovative products and services and comprehensive solutions for convenient, efficient and effective diabetes management spanning from blood glucose monitoring through information management to insulin delivery. The Accu-Chek brand encompasses blood glucose meters, infusion pumps, lancing and data management systems. For more information please visit or


Sanofi strives to help people manage the complex challenge of diabetes by delivering innovative, integrated and personalized solutions. Driven by valuable insights that come from listening to and engaging with people living with diabetes, the Company is forming partnerships to offer diagnostics, therapies, services and devices, including blood glucose monitoring systems. Sanofi markets both injectable and oral medications for people with type 1 or type 2 diabetes.

 Boehringer   The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the familiy-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.